

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM769777

| | | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|-----------------------|--------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT | | |
| NATURE OF CONVEYANCE: | SECURITY INTEREST | | |
| CONVEYING PARTY DATA | | | |
| Name | Formerly | Execution Date | Entity Type |
| Medigate Tech Ltd | | 11/22/2022 | Company: ISRAEL |
| RECEIVING PARTY DATA | | | |
| Name: | Silicon Valley Bank | | |
| Street Address: | 3003 Tasman Drive | | |
| City: | Santa Clara | | |
| State/Country: | CALIFORNIA | | |
| Postal Code: | 95054 | | |
| Entity Type: | Corporation: CALIFORNIA | | |
| PROPERTY NUMBERS Total: 1 | | | |
| Property Type | Number | Word Mark | |
| Serial Number: | 87685583 | MEDIGATE | |
| CORRESPONDENCE DATA | | | |
| Fax Number: | | | |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | | | |
| Email: | julia.brow@us.dlapiper.com | | |
| Correspondent Name: | Julia Brow (DLA PIPER LLP) | | |
| Address Line 1: | 4365 Executive Drive | | |
| Address Line 2: | Suite 1100 | | |
| Address Line 4: | San Diego, CALIFORNIA 92121 | | |
| NAME OF SUBMITTER: | Julia Brow | | |
| SIGNATURE: | /Julia Brow/ | | |
| DATE SIGNED: | 11/23/2022 | | |
| Total Attachments: 9 | | | |
| source=G.7(c)_ _ Medigate_(Ltd)_ _ ISR_IPSA#page1.tif | | | |
| source=G.7(c)_ _ Medigate_(Ltd)_ _ ISR_IPSA#page2.tif | | | |
| source=G.7(c)_ _ Medigate_(Ltd)_ _ ISR_IPSA#page3.tif | | | |
| source=G.7(c)_ _ Medigate_(Ltd)_ _ ISR_IPSA#page4.tif | | | |
| source=G.7(c)_ _ Medigate_(Ltd)_ _ ISR_IPSA#page5.tif | | | |
| source=G.7(c)_ _ Medigate_(Ltd)_ _ ISR_IPSA#page6.tif | | | |

CH \$40.00 87685583

source=G.7(c)_ _ Medigate_(Ltd)_ _ ISR_IPSA#page7.tif

source=G.7(c)_ _ Medigate_(Ltd)_ _ ISR_IPSA#page8.tif

source=G.7(c)_ _ Medigate_(Ltd)_ _ ISR_IPSA#page9.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement (this "Agreement") is entered into as of November 22, 2022 by and between **SILICON VALLEY BANK**, a California corporation, ("**Bank**") and **MEDIGATE TECH LTD**, a company organized under the laws of the State of Israel, with its principal place of business located at _____, Israel ("**Grantor**").

RECITALS

A. Bank has agreed to make certain advances of money and to extend certain financial accommodations to (i) Grantor, (ii) **Claroty Ltd**, a Israeli corporation with its principal place of business at _____, Israel ("**ISR Borrower**"), (iii) **Medigate Corporation**, a Delaware corporation ("**Medigate**") and (iv) **Claroty, Inc.**, a Delaware corporation (together with Medigate, "**US Borrower**") (Grantor, US Borrower, and ISR Borrower hereinafter jointly and severally, individually and collectively, referred to as "**Borrower**") (the "**Loans**") in the amounts and manner set forth in that certain Loan and Security Agreement by and among Bank and Borrower dated as of the date hereof (as the same may be amended, modified or supplemented from time to time, the "**Loan Agreement**"; capitalized terms used herein are used as defined in the Loan Agreement). Bank is willing to make the Loans to Borrower, but only upon the condition, among others, that Grantor shall grant to Bank a security interest in its Copyrights, Trademarks, Patents, and Mask Works (as each term is described below) to secure the obligations of Borrower to Bank.

B. Pursuant to the terms of the Loan Agreement and the Debentures, Grantor has granted to Bank a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of Borrower's obligations to Bank, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

1. Grant of Security Interest. To secure Borrower's obligations to Bank, under the Loan Documents and subject to the terms set forth therein, Grantor grants and pledges to Bank a security interest in all of Grantor's right, title and interest in, to and under its intellectual property (all of which shall collectively be called the "**Intellectual Property Collateral**"), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the "**Copyrights**");

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same,

including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “Patents”);

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the “Trademarks”);

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the “Mask Works”);

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including, without limitation, all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Provided, however, that such Collateral shall not include any “intent-to-use” Trademarks or applications therefor prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise, unless and until acceptable evidence of use of the Trademark has been filed with and accepted by the United States Patent and Trademark Office pursuant to Sections 1(c) or 1(d) of the Lanham Act (15 U.S.C. §§ 1051, et seq.)

2. Recordation. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government officials to record and register this Agreement upon request by Bank.

3. Authorization. Grantor hereby authorizes Bank solely to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property Collateral which Grantor obtains subsequent to the date of this Agreement, and only in connection with such modification to (b) file a duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.

4. Loan Documents. This Agreement has been entered into pursuant to and in conjunction with the Loan Agreement and the Debentures, each of which is hereby incorporated by reference. The provisions of the Loan Agreement and the Debentures shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Bank with respect to the Intellectual Property Collateral are as provided by the Loan Agreement, the Debentures and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.

5. Execution in Counterparts. This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature

page to this Agreement by facsimile or in electronic (i.e., "pdf" or "tif" format) shall be effective as delivery of a manually executed counterpart of this Agreement.

6. Successors and Assigns. This Agreement will be binding on and shall inure to the benefit of the parties hereto and their respective successors and assigns.

7. Governing Law. This Agreement and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement and the transactions contemplated hereby and thereby shall be governed by, and construed in accordance with, the laws of the United States and the State of California, without giving effect to any choice or conflict of law provision or rule (whether the State of California or any other jurisdiction).

8. Termination. The security interest granted hereunder shall terminate automatically upon the termination of Bank's security interests granted under the Loan Agreement and the Debentures. Upon such termination, Bank shall, at Grantor's sole cost and expense, execute all documents and other instruments as may be necessary to evidence the termination of the security interest granted hereunder.


[Signature page follows]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

MEDIGATE TECH LTD

By:

DocuSigned by:

8F5F73308DCC4DE...


Name: Jonathan Langer

Title:
CEO

BANK:

SILICON VALLEY BANK

By:

DocuSigned by:

3B1E05298F174AE...

Name: Sigal Ben Dor

Title:
Operational Relationship Manager

EXHIBIT A

Copyrights

N/A

EXHIBIT B

Patents

| Title | Date Filed/ issued | Status | Patent/Patent Application ID |
|------------------------------------------------------------------------------|--------------------------------------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| ENSURING AVAILABILITY OF MEDICAL DEVICES TO RECEIVE MAINTENANCE | Filed: August 18, 2019 Issued: November 3, 2020 | issued confirmed | US10825566 |
| UTILIZATION-BASED SCHEDULING OF PREVENTATIVE MAINTENANCE FOR MEDICAL DEVICES | August 18, 2019 | The patent application is abandoned as of 29/12/2021 Due to failure to respond to an Office Action | Application Number: US16/543563 Publication number <u>US 2021/0050099</u> |
| REDUCING UNNECESSARY SCHEDULED PREVENTATIVE MAINTENANCE FOR MEDICAL DEVICES | August 18, 2019 | The patent application is abandoned as of 22/2/2021 Due to failure to respond to an Office Action | Application Number: US16/543567 Publication number <u>US 2021/0050100</u> |

| Title | Date Filed/ issued | Status | Patent/Patent Application ID |
|------------------------------------------------------------------------------|--------------------------------------------------|----------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| CROWD-BASED RECOMMENDATIONS OF A VERSION OF FIRMWARE FOR MEDICAL DEVICES | Filed: August 18, 2019 Issued: May 19, 2020 | issued - confirmed | US10658079 |
| DRUG LIBRARY UPDATE MONITORING | August 18, 2019 | The patent application is abandoned as of 18/01/2022 Due to failure to respond to an Office Action | Application Number: US16/543569 Publication number US 2021/0050101 |
| MEDICATION USAGE AUDITING BASED ON ANALYSIS OF INFUSION PUMP NETWORK TRAFFIC | Filed: July 18, 2019 Issued: July 6, 2021 | issued - confirmed | US11056232 |
| NETWORK-BASED CALCULATION OF PREVALENCE OF REPEATED MEDICAL IMAGING | Filed: August 18, 2019 Issued: March 24, 2020 | issued - confirmed | US10600512 |

EXHIBIT C

Trademarks

| Trademark | Jurisdiction | Filing Details | Status | Owner | Office actions |
|------------------|---------------------|-------------------------------------------------------------------------------------------------------------------------------|----------------------|--------------------|-----------------------|
| MEDIGATE | United States | Filing date: November 15, 2017 Publication date: November 6, 2018 Serial number: 87685583 | Registered confirmed | Medigate Tech Ltd. | None |

EXHIBIT D

Mask Works

N/A